Epilepsy Research
Volume 87, Issue 1 , Pages 54-58 , November 2009

Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment?

  • Oğuzhan Öz

      Affiliations

    • Gülhane Military Medical Academy and Faculty, Department of Neurology, Etlik-Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 312 304 4481; fax: +90 312 304 4475.
    • ,
  • Zeki Gökçil

      Affiliations

    • Gülhane Military Medical Academy and Faculty, Department of Neurology, Etlik-Ankara, Turkey
    • ,
  • Semai Bek

      Affiliations

    • Gülhane Military Medical Academy and Faculty, Department of Neurology, Etlik-Ankara, Turkey
    • ,
  • Erdinç Çakır

      Affiliations

    • Gülhane Military Medical Academy and Faculty, Department of Emergency, Biochemistry Laboratory, Etlik-Ankara, Turkey
    • ,
  • Zeki Odabaşı

      Affiliations

    • Gülhane Military Medical Academy and Faculty, Department of Neurology, Etlik-Ankara, Turkey

Received 15 January 2009 ,Revised 16 July 2009 ,Accepted 24 July 2009.

References 

  1. Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia. 1984;25(6):699–704
  2. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res. 2001;47(1–2):27–35
  3. Apeland T, Mansoor MA, Strandjord RE, Vefring H, Kristensen O. Folate, homocysteine and methionine loading in patients on carbamazepine. Acta Neurol. Scand. 2001;103(5):294–299
  4. Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, et al. Tetatogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000;41:1436–1443
  5. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068–2074
  6. Dasheiff RM. Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation on the relationship to sudden cardiac death. J. Clin. Neurophysiol. 1991;8:216–222
  7. Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 2008;295(2):816–825
  8. Eirís JM, Lojo S, Del Río MC, Novo I, Bravo M, Pavón P, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology. 1995;45:1155–1157
  9. Graham I, Daly L, Refsum H, Robinson K, Brattbtrijm L. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775–1778
  10. Huemer M, Ausserer B, Graninger G, Hubmann M, Huemer C, Schlachter K, et al. Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia. 2005;46(10):1677–1683
  11. Isojärvi JI, Pakarinen AJ, Myllylä VV. Serum lipid levels during carbamazepine medication. Arch. Neurol. 1993;50:590–593
  12. James GK, Jones MW, Pudek MR. Homocyst(e)ine levels in patients on phenytoin therapy. Clin. Biochem. 1997;30(8):647–649
  13. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J. Physiol. Pharmacol. 2007;58(June (2)):191–206
  14. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 1999;10:594–600
  15. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis. 2006;189(1):236–240
  16. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler. Suppl. 2003;4(4):61–65
  17. Li X, Breteler MMB, de Bruyne MC, Meinardi H, Hauser WA, Hofman A. Vascular determinants of epilepsy: the Rotterdam study. Epilepsia. 1997;38:1216–1220
  18. Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology. 2004;62:872–877
  19. Luoma PV, MyllYla VV, Soteinemi EA, Lehtien IA, Hokkaen EJ. Plasma high-density lipoprotein cholesterol inepileptics treated with anticonvulants. Eur. Neurol. 1980;19:67–72
  20. May RB, Sunder TR. Hematologic manifestations of longterm valproate therapy. Epilepsia. 1993;34:1098–1101
  21. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  22. Nilsson L, et al. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia. 1997;38(10):1062–1068
  23. Ono H, Sakamoto A, Eguchi T, Fujita N, Nomura S, Ueda H, et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 1997;46(8):959–962
  24. Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999;40(3):345–350
  25. Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N. Engl. J. Med. 1995;332:286–291
  26. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268(7):877–881
  27. Stühlinger MC, Stanger O. Asymmetric dimethyl-l-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr. Drug Metab. 2005;6:3–14
  28. Tamura T, Aiso K, Johnston KE, Black L, Faught E. Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res. 2000;40:7–15
  29. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet. 2001;358:2127–2128
  30. Vallance P. Importance of asymmetric dimethylarginine in cardiovascular risk. Lancet. 2001;358:2096–2097
  31. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 1992;20(Suppl. 12):60–62
  32. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur. J. Clin. Invest. 1995;25(March (3)):176–181
  33. Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res. 2000;41(3):253–257
  34. Yoo J, Lee S. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425–430
  35. Zinellu A, Sotgia S, Scanu B, Deiana L, Carru C. Determination of protein-incorporated methylated arginine reference values in healthy subjects whole blood and evaluation of factors affecting protein methylation. Clin. Biochem. 2008;41(14–15):1218–1223

☆ This study had presented as a poster at Eighteenth Meeting of the European Neurological Society 7–11 June 2008, Nice, France as entitled “Effects of valproic acid and carbamazepine monotherapies on asymmetric dimethylarginine, homocysteine, folate and vitamin B-12 levels: possible links to pathogenesis of epilepsy and complications of medication.”

PII: S0920-1211(09)00200-9

doi: 10.1016/j.eplepsyres.2009.07.011

Epilepsy Research
Volume 87, Issue 1 , Pages 54-58 , November 2009

Article Tools

* Image Usage & Resolution